Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 4, Pages 860
Publisher
MDPI AG
Online
2021-02-19
DOI
10.3390/cancers13040860
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anti‐PD1‐Induced Immune‐Related Adverse Events and Survival Outcomes in Advanced Melanoma
- (2020) Aleksi Suo et al. ONCOLOGIST
- Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis
- (2020) Xiaoxiang Zhou et al. BMC Medicine
- Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab
- (2020) Linda Bouhlel et al. BULLETIN DU CANCER
- 696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial
- (2020) T.K. Choueiri et al. ANNALS OF ONCOLOGY
- The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies
- (2020) Chiao-En Wu et al. BMC CANCER
- Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysis
- (2020) Syed Hussaini et al. CANCER TREATMENT REVIEWS
- Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab
- (2019) Hiroki Ishihara et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
- (2019) Elena Verzoni et al. Journal for ImmunoTherapy of Cancer
- Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review
- (2019) Shaheen Khan et al. SEMINARS IN CANCER BIOLOGY
- Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade
- (2019) Steve Lu et al. JAMA Oncology
- Combination of TMB and CNA stratifies prognostic and predictive responses to immunotherapy across metastatic cancer
- (2019) Li Liu et al. CLINICAL CANCER RESEARCH
- Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors
- (2019) Sophia C Weinmann et al. RHEUMATOLOGY
- The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non–small-cell lung cancer: a real-life retrospective study
- (2019) R. Dupont et al. OncoImmunology
- Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
- (2019) Satya Das et al. Journal for ImmunoTherapy of Cancer
- Safety and Efficacy of Nivolumab for Metastatic Renal Cell Carcinoma: Real-World Results From an Expanded Access Program
- (2018) Ugo De Giorgi et al. BJU INTERNATIONAL
- Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab
- (2018) Koichi Sato et al. LUNG CANCER
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy
- (2018) Maria Giuseppa Vitale et al. PLoS One
- Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
- (2018) Koji Haratani et al. JAMA Oncology
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
- (2018) Jun Gong et al. Journal for ImmunoTherapy of Cancer
- Endocrine toxicity of cancer immunotherapy targeting immune checkpoints
- (2018) Lee-Shing Chang et al. ENDOCRINE REVIEWS
- A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers
- (2018) S. N. Gettinger et al. Nature Communications
- Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non–small-cell Lung Cancer
- (2018) Mathieu Grangeon et al. Clinical Lung Cancer
- Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis
- (2018) Biagio Ricciuti et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application
- (2018) Nancy Tray et al. Cancer Immunology Research
- Comprehensive screening for PD-L1 expression in thyroid cancer
- (2017) Soomin Ahn et al. ENDOCRINE-RELATED CANCER
- The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma
- (2017) Emma S Scott et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systemic Therapy for Metastatic Renal-Cell Carcinoma
- (2017) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer
- (2017) Hye In Kim et al. OncoImmunology
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
- (2015) M. Freeman-Keller et al. CLINICAL CANCER RESEARCH
- Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
- (2015) Hansje-Eva Teulings et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autoimmune Thyroid Disease Elicited by NY-ESO-1 Vaccination
- (2013) Roberto Vita et al. THYROID
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started